Daniel H Sterman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7778822/publications.pdf

Version: 2024-02-01

141 papers

8,103 citations

50244 46 h-index 86 g-index

168 all docs

168 docs citations

168 times ranked 7430 citing authors

#	Article	IF	CITATIONS
1	Immunotherapy for mesothelioma: Moving beyond single immune check point inhibition. Lung Cancer, 2022, 165, 91-101.	0.9	5
2	Lower Airway Dysbiosis Affects Lung Cancer Progression. Cancer Discovery, 2021, 11, 293-307.	7.7	139
3	Lung Cancer Characteristics in the World Trade Center Environmental Health Center. International Journal of Environmental Research and Public Health, 2021, 18, 2689.	1.2	7
4	Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial. Lung Cancer, 2021, 154, 5-12.	0.9	8
5	Microbial signatures in the lower airways of mechanically ventilated COVID-19 patients associated with poor clinical outcome. Nature Microbiology, 2021, 6, 1245-1258.	5.9	101
6	COVID-19 in Pulmonary Artery Hypertension (PAH) Patients: Observations from a Large PAH Center in New York City. Diagnostics, 2021, 11, 128.	1.3	22
7	Improving electromagnetic navigation: One nodule at a time. Respirology, 2020, 25, 130-131.	1.3	O
8	Value of metalloproteinases in predicting COPD in heavy urban smokers. Respiratory Research, 2020, 21, 228.	1.4	5
9	Clinical Outcomes in Critically Ill Coronavirus Disease 2019 Patients: A Unique New York City Public Hospital Experience. , 2020, 2, e0188.		18
10	A Propensity-Matched Cohort Study of Tocilizumab in Patients With Coronavirus Disease 2019., 2020, 2, e0283.		17
11	Management of Indwelling Tunneled Pleural Catheters. Chest, 2020, 158, 2221-2228.	0.4	25
12	Bronchoscopic intratumoural therapies for non-small cell lung cancer. European Respiratory Review, 2020, 29, 200028.	3.0	17
13	Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?. Frontiers in Oncology, 2020, 10, 343.	1.3	48
14	Mesothelioma: is chemotherapy alone a thing of the past?. , 2020, , 232-249.		1
15	Tumor-draining lymph nodes demonstrate a suppressive immunophenotype in patients with non-small cell lung cancer assessed by endobronchial ultrasound-guided transbronchial needle aspiration: A pilot study. Lung Cancer, 2019, 137, 94-99.	0.9	10
16	A TALE OF A TRAVELING FLUKE. Chest, 2019, 156, A1264-A1265.	0.4	0
17	Malignant Mesothelioma: Has Anything Changed?. Seminars in Respiratory and Critical Care Medicine, 2019, 40, 347-360.	0.8	23
18	Intrapleural immunotherapy: An update on emerging treatment strategies for pleural malignancy. Clinical Respiratory Journal, 2019, 13, 272-279.	0.6	12

#	Article	IF	CITATIONS
19	DIAGNOSTIC AND MANAGEMENT CHALLENGES IN A CASE OF INSIDIOUS PNEUMOCYSTIS JIROVECII PNEUMONIA (PCP) WITH RESULTANT FULMINANT LUNG DESTRUCTION IN A NON-HIV IMMUNOCOMPROMISED PATIENT. Chest, 2019, 156, A539-A540.	0.4	0
20	Summary for Clinicians: Clinical Practice Guideline for Management of Malignant Pleural Effusions. Annals of the American Thoracic Society, 2019, 16, 17-21.	1.5	12
21	First-ever Abscopal Effect after Palliative Radiotherapy and Immuno-gene Therapy for Malignant Pleural Mesothelioma. Cureus, 2019, 11, e4102.	0.2	17
22	Immunological Aspects of Cryoablation of Non–Small Cell Lung Cancer: A Comprehensive Review. Journal of Thoracic Oncology, 2018, 13, 624-635.	0.5	35
23	Intracavitary Therapeutics for Pleural Malignancies. Clinics in Chest Medicine, 2018, 39, 195-209.	0.8	3
24	Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion. Molecular Therapy, 2018, 26, 1198-1205.	3.7	24
25	Updates in the diagnosis and treatment of malignant pleural mesothelioma. Current Opinion in Pulmonary Medicine, 2018, 24, 319-326.	1.2	27
26	Reply to D. de Fonseka et al. Journal of Clinical Oncology, 2018, 36, 2746-2747.	0.8	0
27	Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2018, 36, 1343-1373.	0.8	324
28	Stereotactic Body Radiotherapy for Early-Stage Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline. Journal of Clinical Oncology, 2018, 36, 710-719.	0.8	127
29	Management of Malignant Pleural Effusions. An Official ATS/STS/STR Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 839-849.	2.5	284
30	The Immune Landscape of Non–Small-Cell Lung Cancer. Utility of Cytologic and Histologic Samples Obtained through Minimally Invasive Pulmonary Procedures. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 24-38.	2.5	14
31	Airway Microbiota Is Associated with Upregulation of the PI3K Pathway in Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1188-1198.	2.5	232
32	Recent Advances in Bronchoscopic Treatment of Peripheral Lung Cancers. Chest, 2017, 151, 674-685.	0.4	61
33	High Complication Rate after Introduction of Transbronchial Cryobiopsy into Clinical Practice at an Academic Medical Center. Annals of the American Thoracic Society, 2017, 14, 851-857.	1.5	81
34	Checkpoint Blockade in Lung Cancer and Mesothelioma. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 274-282.	2.5	59
35	Local Immunotherapy of Cancer: Innovative Approaches to Harnessing Tumor-Specific Immune Responses. Journal of the National Cancer Institute, 2017, 109, .	3.0	31
36	Extended Pleurectomy-Decortication–Based Treatment for Advanced Stage Epithelial Mesothelioma Yielding a Median Survival of Nearly Three Years. Annals of Thoracic Surgery, 2017, 103, 912-919.	0.7	103

#	Article	IF	Citations
37	Fifteen-Year Follow-Up of the NYU Lung Biomarker Screening Cohort: Indolent-Prevalent Screen-Detected Lung Cancers Demonstrate a Less Aggressive Form of Pulmonary Malignancy. Chest, 2017, 152, A626.	0.4	0
38	Harnessing the Power of the Host: Improving Dendritic Cell Vaccines for Malignant Pleural Mesothelioma. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 943-945.	2.5	5
39	Bronchoscopic Transparenchymal Nodule Access: Feasibility and Safety in an Endoscopic Unit. Respiration, 2016, 91, 302-306.	1.2	39
40	Enrichment of the lung microbiome with oral taxa is associated with lung inflammation of a Th17 phenotype. Nature Microbiology, 2016, 1, 16031.	5.9	436
41	Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy. Clinical Cancer Research, 2016, 22, 3791-3800.	3.2	77
42	Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. European Journal of Cardio-thoracic Surgery, 2016, 49, 1324-1333.	0.6	33
43	Phase I study of gene mediated cytotoxic immunotherapy (GMCI) for patients with malignant pleural effusion (MPE) Journal of Clinical Oncology, 2016, 34, 3081-3081.	0.8	0
44	Transbronchial Cryobiopsies: Evidence Moving at Glacial Speed?. Chest, 2015, 148, 822A.	0.4	1
45	High Yield of Bronchoscopic Transparenchymal Nodule Access Real-Time Image-Guided Sampling in a Novel Model of Small Pulmonary Nodules in Canines. Chest, 2015, 147, 700-707.	0.4	23
46	Endobronchial Ultrasound-guided Sheath Placement to Guide Transbronchial Biopsy of Mediastinal Lymphadenopathy and Lung Mass. Journal of Bronchology and Interventional Pulmonology, 2015, 22, 158-161.	0.8	2
47	Bronchoscopic transparenchymal nodule access (BTPNA): first in human trial of a novel procedure for sampling solitary pulmonary nodules. Thorax, 2015, 70, 326-332.	2.7	99
48	The Use of Indwelling Tunneled Pleural Catheters for Recurrent Pleural Effusions in Patients With Hematologic Malignancies. Chest, 2015, 148, 752-758.	0.4	48
49	Bringing Comfort to Endobronchial Ultrasound Bronchoscopy. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 727-728.	2.5	3
50	Interventional Bronchoscopy in 2015. Removing Endoluminal and Methodological Obstructions. Annals of the American Thoracic Society, 2015, 12, 1265-1266.	1.5	4
51	Ultrathin Is In: A New Option for Peripheral Pulmonary Nodules. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 405-407.	2.5	3
52	The use of convex probe endobronchial ultrasound-guided transbronchial needle aspiration in a pediatric population: A multicenter study. Pediatric Pulmonology, 2014, 49, 807-815.	1.0	39
53	Stent-Mediated Gene Delivery for Site-Specific Transgene Administration to the Airway Epithelium and Management of Tracheobronchial Tumors. Respiration, 2014, 88, 406-417.	1.2	7
54	The IBV Valve Trial. Journal of Bronchology and Interventional Pulmonology, 2014, 21, 288-297.	0.8	53

#	Article	IF	Citations
55	Prognostic Value of Primary Tumor FDG Uptake for Occult Mediastinal Lymph Node Involvement in Clinically N2/N3 Node-negative Non–Small Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 135-139.	0.6	14
56	Gene Therapy: Charting a Future Courseâ€"Summary of a National Institutes of Health Workshop, April 12, 2013. Human Gene Therapy, 2014, 25, 488-497.	1.4	12
57	Feasibility and Safety of Bronchoscopic Transparenchymal Nodule Access in Canines. Chest, 2014, 145, 833-838.	0.4	26
58	Advances in Pleural Disease Management Including Updated Procedural Coding. Chest, 2014, 146, 508-513.	0.4	14
59	The diagnostic efficacy of combining bronchoscopic tissue biopsy and endobronchial ultrasoundâ€guided transbronchial needle aspiration for the diagnosis of malignant lesions in the lung. Diagnostic Cytopathology, 2013, 41, 929-935.	0.5	8
60	Intracavitary Therapeutics for Pleural Malignancies. Clinics in Chest Medicine, 2013, 34, 501-513.	0.8	6
61	Malignant Pleural Mesothelioma. Clinics in Chest Medicine, 2013, 34, 99-111.	0.8	39
62	Point: Should Epidermal Growth Factor Receptor Mutations Be Routinely Tested for in Patients With Lung Cancer? Yes. Chest, 2013, 143, 597-600.	0.4	2
63	Comparison of Moderate versus Deep Sedation for Endobronchial Ultrasound Transbronchial Needle Aspiration. Annals of the American Thoracic Society, 2013, 10, 121-126.	1.5	93
64	Endoscopic Lung Volume Reduction. An American Perspective. Annals of the American Thoracic Society, 2013, 10, 667-679.	1.5	5
65	Rebuttal From Dr Sterman. Chest, 2013, 143, 602-603.	0.4	0
66	Validation of an Interventional Pulmonary Examination. Chest, 2013, 143, 1667-1670.	0.4	26
67	A Remarkable Time for the American Association for Bronchology and Interventional Pulmonology. Journal of Bronchology and Interventional Pulmonology, 2012, 19, 265-267.	0.8	3
68	Secondary Carina Y-Stent Placement for Post–Lung-Transplant Bronchial Stenosis. Journal of Bronchology and Interventional Pulmonology, 2012, 19, 109-114.	0.8	9
69	A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction. Clinical Cancer Research, 2012, 18, 858-868.	3.2	304
70	Novel Intrapleural Therapies for Malignant Diseases. Respiration, 2012, 83, 277-292.	1.2	20
71	The Revolution is Here…Long Live the Revolution. Journal of Bronchology and Interventional Pulmonology, 2012, 19, 1-2.	0.8	O
72	Bronchoscopy., 2012, , 154-173.		3

#	Article	IF	Citations
73	Gene therapy in interventional pulmonology: Interferon gene delivery with focus on thoracic malignancies. Current Respiratory Care Reports, 2012, 1, 54-66.	0.6	2
74	Radical Pleurectomy and Intraoperative Photodynamic Therapy for Malignant Pleural Mesothelioma. Annals of Thoracic Surgery, 2012, 93, 1658-1667.	0.7	132
75	Photodynamic therapy for the treatment of non-small cell lung cancer. Journal of Thoracic Disease, 2012, 4, 63-75.	0.6	87
76	Gene Therapy for Lung Neoplasms. Clinics in Chest Medicine, 2011, 32, 865-885.	0.8	21
77	Airway Complications Following Lung Transplantation. Clinics in Chest Medicine, 2011, 32, 357-366.	0.8	21
78	The Role of On-site Cytological Evaluation for Suspected Sarcoidosis. Chest, 2011, 140, 494A.	0.4	0
79	Treatment of a malignant peripheral nerve sheath tumor and its complications through a multidisciplinary approach. Journal of Neurosurgery: Pediatrics, 2011, 7, 543-548.	0.8	9
80	Pilot randomized study comparing two techniques of airway anaesthesia during curvilinear probe endobronchial ultrasound bronchoscopy (CPâ€EBUS). Respirology, 2011, 16, 102-106.	1.3	20
81	Endobronchial Valve Treatment for Prolonged Air Leaks of the Lung: A Case Series. Annals of Thoracic Surgery, 2011, 91, 270-273.	0.7	102
82	A Trial of Intrapleural Adenoviral-mediated Interferon-α2b Gene Transfer for Malignant Pleural Mesothelioma. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 1395-1399.	2.5	80
83	Diagnosis of Idiopathic Tracheal Stenosis and Treatment With Papillotome Electrocautery and Balloon Bronchoplasty. Respiratory Care, 2011, 56, 1617-1620.	0.8	8
84	Standardization of Interventional Pulmonology Training: Response. Chest, 2010, 138, 761-762.	0.4	0
85	An Approach to Interventional Pulmonary Fellowship Training. Chest, 2010, 137, 195-199.	0.4	67
86	Donor transmission of malignant melanoma in a lung transplant recipient 32â€fyears after curative resection. Transplant International, 2010, 23, e26-e31.	0.8	27
87	Evaluation of an Attenuated Vesicular Stomatitis Virus Vector Expressing Interferon- \hat{l}^2 for Use in Malignant Pleural Mesothelioma: Heterogeneity in Interferon Responsiveness Defines Potential Efficacy. Human Gene Therapy, 2010, 21, 51-64.	1.4	64
88	A Phase I Trial of Repeated Intrapleural Adenoviral-mediated Interferon- \hat{l}^2 Gene Transfer for Mesothelioma and Metastatic Pleural Effusions. Molecular Therapy, 2010, 18, 852-860.	3.7	120
89	Advances in Diagnostic Bronchoscopy. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 589-597.	2.5	62
90	Malignant Pleural Mesothelioma. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 1282-1284.	2.5	0

#	Article	IF	Citations
91	Gene Therapy for Malignant Pleural Mesothelioma. , 2010, , 95-111.		0
92	Short-term Placement of Multiple Self-expandable Metallic Stents for the Treatment of Bilateral Bronchial Dehiscences Complicating Lung Transplantation. Journal of Bronchology and Interventional Pulmonology, 2009, 16, 63-65.	0.8	3
93	Kinetics of Soluble Mesothelin in Patients with Malignant Pleural Mesothelioma during Treatment. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 950-954.	2.5	65
94	Management of endobronchial metastasis of colorectal carcinoma. Techniques in Gastrointestinal Endoscopy, 2009, 11, 146-153.	0.3	0
95	Airway stenting for malignant aerodigestive fistulae: A critical review of the literature and treatment recommendations. Techniques in Gastrointestinal Endoscopy, 2009, 11, 118-126.	0.3	O
96	Endotracheal Spindle Cell Lipoma Presenting as a Chronic Cough. Journal of Bronchology and Interventional Pulmonology, 2009, 16, 105-107.	0.8	1
97	Endobronchial Ultrasound. Clinical Pulmonary Medicine, 2009, 16, 337-342.	0.3	1
98	Y-STENT PLACEMENT IN THE SECONDARY CARINA FOR POST-TRANSPLANT BRONCHIAL STENOSIS. Chest, 2009, 136, 78S.	0.4	0
99	What's the Connection?. New England Journal of Medicine, 2008, 358, 626-632.	13.9	21
100	ANALYSIS OF ENDOBRONCHIAL ULTRASONOGRAPHIC FEATURES IN BENIGN AND MALIGNANT MEDIASTINAL LYMPH NODES. Chest, 2008, 134, 13P.	0.4	0
101	Bronchoscopy. , 2008, , 177-196.		5
102	Gene therapy in pleural diseases., 2008,, 613-619.		0
103	A Phase I Clinical Trial of Single-Dose Intrapleural IFN-β Gene Transfer for Malignant Pleural Mesothelioma and Metastatic Pleural Effusions: High Rate of Antitumor Immune Responses. Clinical Cancer Research, 2007, 13, 4456-4466.	3.2	146
104	Cytokine Gene Therapy for Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2007, 2, 265-267.	0.5	14
105	Malignant Pleural Effusions. Chest, 2007, 132, 1036-1041.	0.4	52
106	A multicenter trial of an intrabronchial valve for treatment of severe emphysema. Journal of Thoracic and Cardiovascular Surgery, 2007, 133, 65-73.e2.	0.4	174
107	Transbronchial Needle Injection: A Systematic Review of a New Diagnostic and Therapeutic Paradigm. Respiration, 2006, 73, 78-89.	1.2	24
108	Blockade of TNF-α Decreases Both Inflammation and Efficacy of Intrapulmonary Ad.IFNβ Immunotherapy in an Orthotopic Model of Bronchogenic Lung Cancer. Molecular Therapy, 2006, 13, 910-917.	3.7	18

#	Article	IF	CITATIONS
109	Interferon \hat{I}^2 adenoviral gene therapy in a patient with ovarian cancer. Nature Clinical Practice Oncology, 2006, 3, 633-639.	4.3	29
110	Tumors of the Mediastinum. Chest, 2005, 128, 2893-2909.	0.4	452
111	Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma. Respirology, 2005, 10, 266-283.	1.3	101
112	Intrapulmonary IFN-β Gene Therapy Using an Adenoviral Vector Is Highly Effective in a Murine Orthotopic Model of Bronchogenic Adenocarcinoma of the Lung. Cancer Research, 2005, 65, 8379-8387.	0.4	45
113	Long-term Follow-up of Patients with Malignant Pleural Mesothelioma Receiving High-Dose Adenovirus Herpes Simplex Thymidine Kinase/Ganciclovir Suicide Gene Therapy. Clinical Cancer Research, 2005, 11 , 7444-7453.	3.2	125
114	Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. Cancer Biology and Therapy, 2005, 4, 342-346.	1.5	107
115	Gene Therapy for Malignant Pleural Mesothelioma. Hematology/Oncology Clinics of North America, 2005, 19, 1147-1173.	0.9	9
116	Endobronchial Gene Therapy. Seminars in Respiratory and Critical Care Medicine, 2004, 25, 433-442.	0.8	5
117	Outpatient Management of Malignant Pleural Effusions with Small-Bore, Tunneled Pleural Catheters. Respiration, 2004, 71, 559-566.	1.2	130
118	Granulocyte-Macrophage Colony-Stimulating Factor Gene-Modified Autologous Tumor Vaccines in Non-Small-Cell Lung Cancer. Journal of the National Cancer Institute, 2004, 96, 326-331.	3.0	239
119	Immuno-gene therapy with interferon- \hat{l}^2 before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma. Journal of Thoracic and Cardiovascular Surgery, 2004, 127, 123-130.	0.4	58
120	EUS staging of primary lung carcinoma: are we ready for it?. Gastrointestinal Endoscopy, 2004, 59, 393-395.	0.5	1
121	Diagnosis and staging of "other bronchial tumors― Chest Surgery Clinics of North America, 2003, 13, 79-94.	0.8	12
122	A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma. Annals of Thoracic Surgery, 2003, 75, 952-959.	0.7	125
123	Bronchial sleeve resection for posttransplant stricture. Annals of Thoracic Surgery, 2003, 76, 2075-2076.	0.7	17
124	Phase I Trial of Intravenous Administration of PV701, an Oncolytic Virus, in Patients With Advanced Solid Cancers. Journal of Clinical Oncology, 2002, 20, 2251-2266.	0.8	343
125	Gene therapy for lung neoplasms. Clinics in Chest Medicine, 2002, 23, 265-277.	0.8	20
126	Cardiopulmonary bypass for bilateral sequential lung transplantation in patients with chronic obstructive pulmonary disease without adverse effect on lung function or clinical outcome. Journal of Thoracic and Cardiovascular Surgery, 2002, 124, 241-249.	0.4	62

#	Article	IF	Citations
127	Treatment of Mesothelioma Using Adenoviral-Mediated Delivery of Herpes Simplex Virus Thymidine Kinase Gene in Combination with Ganciclovir., 2002,, 493-503.		0
128	Detection of SV40 DNA sequences in malignant mesothelioma specimens from the United States, but not from Turkey. Journal of Cellular Biochemistry, 2002, 84, 455-9.	1.2	10
129	Bronchial anastomotic stricture caused by ossification of an intercostal muscle flap. Annals of Thoracic Surgery, 2001, 71, 1700-1702.	0.7	34
130	Use of an Implantable Pleural Catheter for Trapped Lung Syndrome in Patients With Malignant Pleural Effusion. Chest, 2001, 119, 1641-1646.	0.4	176
131	Treatment of Mesotheliomatous Pleural Effusion. Journal of Bronchology, 2001, 8, 47-53.	0.2	0
132	Interventional Pulmonology. New England Journal of Medicine, 2001, 344, 740-749.	13.9	175
133	A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma. Cancer Gene Therapy, 2000, 7, 1511-1518.	2.2	48
134	Advances in the Treatment of Malignant Pleural Mesothelioma. Chest, 1999, 116, 504-520.	0.4	139
135	GENE THERAPY FOR MALIGNANT PLEURAL MESOTHELIOMA. Hematology/Oncology Clinics of North America, 1998, 12, 553-568.	0.9	54
136	Impact of Preexisting and Induced Humoral and Cellular Immune Responses in an Adenovirus-Based Gene Therapy Phase I Clinical Trial for Localized Mesothelioma. Human Gene Therapy, 1998, 9, 2121-2133.	1.4	196
137	Adenovirus-Mediated Herpes Simplex Virus Thymidine Kinase/Ganciclovir Gene Therapy in Patients with Localized Malignancy: Results of a Phase I Clinical Trial in Malignant Mesothelioma. Human Gene Therapy, 1998, 9, 1083-1092.	1.4	328
138	Metabolic Imaging of Malignant Pleural Mesothelioma With Fluorodeoxyglucose Positron Emission Tomography. Chest, 1998, 114, 713-722.	0.4	237
139	Safety of Intrapleurally Administered Recombinant Adenovirus Carrying Herpes Simplex Thymidine Kinase DNA Followed by Ganciclovir Therapy in Nonhuman Primates. Human Gene Therapy, 1996, 7, 2225-2233.	1.4	40
140	Treatment of Advanced Mesothelioma with the Recombinant Adenovirus H5.010RSVTK: A Phase 1 Trial (BB-IND 6274). Human Gene Therapy, 1996, 7, 2047-2057.	1.4	32
141	The Role of Immunosuppression in the Efficacy of Cancer Gene Therapy Using Adenovirus Transfer of the Herpes Simplex Thymidine Kinase Gene. Annals of Surgery, 1995, 222, 298-310.	2.1	33